The move follows Arm’s recent foray into direct chip sales with the Meta deal, signaling a major shift in the data center processor landscape.
The rate of cGVHD-free survival was 78% at 1 year in patients who received Orca-T compared with 38% among patients who ...
During a live event, Catherine J. Lee, MD, MS, discussed the efficacy and safety results of various trials of approved agents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback